How Teva Pharmaceutical Industries (TEVA) Story Is Shifting With Duvakitug R&D And Biosimilars [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
The model fair value for Teva Pharmaceutical Industries has shifted slightly, moving from US$37.82 to US$38.18 per share. Analysts are linking this change to updated views on duvakitug, core neuroscience and immunology R&D, the long term build out of biosimilars, and how Teva handles capital allocation. As you read on, you will see how these moving parts are shaping the evolving Teva story and what to watch next in the analyst narrative. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Teva Pharmaceutical Industries. What Wall Street Has Been Saying ?? Bullish Takeaways Piper Sandler lifted its Teva price target to US$41 from US$40 after meetings with management, citing management's approach to R&D, the build out of core neuroscience and immunology, and the vision for the biosimilars franchise. BofA raised its Teva price target to US$38 from US$37 following Phase 2 maintenance data for duvakitug in inflamma
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva Launches Home Groundâ„¢ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care PartnersGlobeNewswire
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable ClinicsGlobeNewswire
- Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy [Seeking Alpha]Seeking Alpha
- Teva Pharmaceutical Industries (TEVA) had its price target raised by Bank of America Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- Teva Pharmaceutical Industries Limited (TEVA): Billionaire Stan Druckenmiller Trims Position [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form ARS
- 3/31/26 - Form DEF
- TEVA's page on the SEC website